The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
about
Chapter 7: PharmacogenomicsCytochrome P4502C9: an enzyme of major importance in human drug metabolismmicroRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessmentPharmacogenetics of healthy volunteers in Puerto RicoClinical relevance of genetic polymorphisms in the human CYP2C subfamilyWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsDistal effect of amino acid substitutions in CYP2C9 polymorphic variants causes differences in interatomic interactions against (S)-warfarinCharacterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentInvestigating the Role of Plasma Glucose Concentration as a Phenotypic Marker for CYP2C9 Genetic Variants, in the Diabetic Population of GujaratPharmacogenetics of anticoagulants.Meta-analysis of cytochrome P-450 2C9 polymorphism and colorectal cancer riskGenetics of warfarin sensitivity in an emergency department population with thromboembolic.Genetic predisposition to acute gastrointestinal bleeding after NSAIDs useMutaCYP: Classification of missense mutations in human cytochromes P450Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrelPharmacogenetics of analgesic drugsCloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps.Functional Characterization of Human CYP2C9 Allelic Variants in COS-7 Cells.Role of pharmacogenomics in the management of traditional and novel oral anticoagulantsPharmacogenetics and cardiovascular disease--implications for personalized medicineComputational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 DiabetesCytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.Fatty acid hydroperoxides support cytochrome P450 2S1-mediated bioactivation of benzo[a]pyrene-7,8-dihydrodiol.Functional characterization of human cytochrome P450 2S1 using a synthetic gene-expressed protein in Escherichia coli.Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone.CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.CYP2C9 polymorphism and warfarin dose requirements.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations.Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population
P2860
Q21563496-FC0AF2A1-023D-448C-955B-06A1DA9C6169Q24683497-1CC8569A-5F78-44A3-B395-84A18ECAEB2FQ26778918-2E196F5F-4CF9-4327-83C4-D06B764653A0Q26779038-6EC5B1B6-D55A-4A1F-BBD5-814F009FB12DQ28362533-89F599A9-643D-4981-81B3-084C15272639Q28395337-6448A888-AC9B-487E-A1B1-0CCEC5D49FB0Q28536483-3BB1494D-57CE-47A6-9CFB-9928200F4CAEQ30939373-CA30995C-8E64-499D-8AA7-C0084D7FB4B1Q30977143-61BB54E9-FBB8-4C84-B28F-E057D1C43732Q33555327-DE1AA2D8-8DD8-44C5-9815-34EE7B9ED569Q34219746-9DB7682D-F23A-4900-881E-656ACBFC54DFQ34474124-B4BE61C0-743C-4B76-A8DB-7AED03135E8AQ34934523-937B7FF2-C430-4FD7-A822-BC2832ED150AQ35046080-F6CB3C91-3080-4337-B661-33FB9BA67A25Q35215197-D9D9DA2D-2D0E-47C0-A21F-78AC053DABA3Q35661209-3F6F91AC-3CD2-447A-8EC4-71024F935F7BQ35803966-53349F09-0CFA-4954-B065-6EF0A7EED1ABQ35827129-37966813-3488-4BF6-A12F-B15B29C827F0Q36110592-2BB16259-BBF5-4D2F-90EA-5AC433826416Q36316100-619D67BE-006F-4939-AA49-6414A737372FQ36740734-72A2123D-3B25-490F-8B28-F92EF2C614CEQ36831692-9AC4B4EC-D49B-4539-98E5-3A9EF4830B98Q36848449-E28E00C9-5431-4B1C-80D9-F65F611A387DQ36974672-103F3D6F-2A26-44B6-B923-CF66768FF9C5Q37134345-BD6A1A41-6C53-4A04-8ACA-7B4EF6EF65DFQ37219846-329DC20B-7A59-4B5B-9A0D-8E6BA5A3FE72Q37415810-288A9732-9086-47E4-9A34-E65882B205E6Q37415818-15DE1915-C542-4FFC-992E-29B4FF755840Q37429282-2A258451-8AD9-49C5-AF40-7DCE0D8AD69FQ40371454-4B6E5257-5856-499F-9341-00118B2EE150Q42780483-0560CF15-AD81-4BC8-ADB6-041C407DE9CEQ42780491-219F5214-5CAA-4C4D-A7B8-55EB84FF2397Q47570862-6CF9F667-7129-4B57-9F07-331E418E4F2AQ48503138-ACBF1D76-DDFC-472E-A974-B8FAD45A75DDQ58581001-A853364A-1956-4CC5-B3DF-22955CD0BFC9
P2860
The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The R144C change in the CYP2C9 ...... ytochrome P450 oxidoreductase.
@en
The R144C change in the CYP2C9 ...... ytochrome P450 oxidoreductase.
@nl
type
label
The R144C change in the CYP2C9 ...... ytochrome P450 oxidoreductase.
@en
The R144C change in the CYP2C9 ...... ytochrome P450 oxidoreductase.
@nl
prefLabel
The R144C change in the CYP2C9 ...... ytochrome P450 oxidoreductase.
@en
The R144C change in the CYP2C9 ...... ytochrome P450 oxidoreductase.
@nl
P1476
The R144C change in the CYP2C9 ...... ytochrome P450 oxidoreductase.
@en
P2093
P304
P577
1997-06-01T00:00:00Z